TY - JOUR AU - Jain, Alok Pal PY - 2017/11/03 Y2 - 2024/03/29 TI - Novel Drug Delivery System Based on Docetaxel-loaded Gelatin Nanoparticles Treatment in Human Breast Cancer Cell Line MCF-7 JF - Asian Journal of Pharmaceutics (AJP) JA - AJP VL - 11 IS - 03 SE - ORIGINAL ARTICLES DO - 10.22377/ajp.v11i03.1505 UR - https://asiapharmaceutics.info/index.php/ajp/article/view/1505 SP - AB - Background: The goal of the present investigation was to evaluate docetaxel (DOC)-loaded gelatin nanoparticles<br />for cancer therapy. Materials and Methods: DOC-loaded gelatin nanoparticles using ultraviolet-visible<br />spectroscopy, X-ray diffraction, particle size and size distribution, scanning electron microscopy, drug entrapment<br />efficiency, infrared, and in vitro drug release were characterized. The viability of MCF-7 breast cancer (BC) cells<br />was determined by MTT. Cell sensitivity to drugs and growth curves were measured by MTT assay. Changes<br />of cell morphology and ultrastructure were examined by optical and electron microscopy. Results: Solubility,<br />crystallinity, and the crystal properties of an active pharmaceutical ingredient play a critical role in the value<br />chain of pharmaceutical development, manufacturing, and formulation. The rate of drug release for formulation<br />stored at 45°C ± 1°C was increased as compared with the fresh formulation; it might be due to the formation of<br />more pores in the nanoparticles due to evaporation of residual amount of solvent. The in vitro release studies of<br />drug-loaded nanoparticles were conducted at 37 ± 0.5 and 100 rpm using phosphate buffer pH 7.4 (900 ml) in a<br />USP dissolution apparatus under sink condition. DOC-loaded gelatin nanoparticles depleted the viability of MCF<br />human breast cell line. In this study, MCF BC cell line revealed growth inhibition in a dose-dependent manner<br />when treated DOC-loaded gelatin nanoparticles at concentrations ranging from 5 to 100 μg. Conclusion: The<br />DOC-loaded gelatin nanoparticles displayed differential cytotoxicity toward MCF7 cancer cells. These biogenic<br />nanoparticles are biocompatible and found to be good candidates for sustained drug delivery in diseases like<br />cancer. ER -